Cytokine Testing

Advanced Cytokine Testing: High‑Parameter Multiplex Immunoassay, Functional Bioactivity, and Intracellular Signalling Profiling for Immune System Monitoring

Cytokines are a diverse group of small glycoproteins that mediate intercellular communication in the immune system, orchestrating responses to infection, inflammation, tissue repair, and malignancy. The cytokine network comprises interleukins, interferons, tumour necrosis factors, chemokines, growth factors, and colony‑stimulating factors—each exhibiting pleiotropic, redundant, and often opposing actions. Accurate and comprehensive cytokine testing has become indispensable for understanding the pathophysiology of autoimmune diseases, chronic inflammatory conditions, infectious diseases, and immune‑related adverse events in oncology. However, measuring a single cytokine in isolation provides a fragmentary view; clinicians and researchers increasingly demand a multiplexed, functionally relevant, and dynamically responsive assessment that captures the net biological effect of the entire cytokine milieu. Our laboratory delivers a fully integrated cytokine testing service that combines ultrasensitive multiplex chemiluminescent immunoassays, cell‑based functional bioactivity assays, and phospho‑signalling network analysis, providing an unparalleled depth of analytical and biological insight for precision immunodiagnostics and therapeutic monitoring.

The Clinical Rationale for Multiplex and Functional Cytokine Profiling

Conventional single‑analyte ELISA or low‑plex bead arrays are limited by their inability to capture the simultaneous interplay of pro‑inflammatory, anti‑inflammatory, and regulatory cytokines that define the net immune status. Furthermore, immunoassays quantify immunoreactive mass, which may not correspond to biological activity due to the presence of precursor forms, cleavage products, soluble receptor complexes, or naturally occurring autoantibodies. For instance, TNF‑α can be neutralised by soluble receptors, IL‑2 can be trapped by soluble CD25, and IL‑1β requires inflammasome‑mediated cleavage for full activity. Our standard comprehensive cytokine panel includes IL‑1β, IL‑2, IL‑4, IL‑5, IL‑6, IL‑7, IL‑8, IL‑10, IL‑12p70, IL‑13, IL‑17A, IL‑18, IL‑21, IL‑22, IL‑23, IL‑33, IFN‑α, IFN‑γ, TNF‑α, TNF‑β, GM‑CSF, MCP‑1, MIP‑1α, MIP‑1β, and RANTES—totalling 25 analytes covering the major Th1, Th2, Th17, Treg, and innate immune axes, as well as chemotactic and haematopoietic factors. This multiplex panel is performed on a validated chemiluminescent platform with limits of quantification (LOQs) in the sub‑pg/mL range for most analytes, enabling detection even in healthy subjects and in biofluids with low cytokine concentrations.

To complement static concentration data, we offer functional bioactivity assays for key cytokines including TNF‑α, IFN‑γ, IL‑2, IL‑6, IL‑10, and IL‑17. These cell‑based assays use validated reporter cell lines (e.g., NF‑κB‑luciferase for TNF, ISRE‑luciferase for IFN, CTLL‑2 proliferation for IL‑2, B9 hybridoma growth for IL‑6) to quantify the biological signalling capacity of endogenous cytokines, expressed in international units (IU/mL) referenced to WHO standards. Additionally, we provide neutralisation assays that measure the fraction of bioactivity blockable by specific anti‑cytokine antibodies, which is particularly useful for patients on biologic therapies (e.g., anti‑TNF, anti‑IL‑6, anti‑IL‑17) to assess the actual level of free, active cytokine that remains unneutralised by the drug. For a more granular view of signal transduction, we perform intracellular phospho‑flow cytometry to measure phosphorylation of STAT proteins (pSTAT1, pSTAT3, pSTAT4, pSTAT5, pSTAT6) and MAPKs (p‑p38, p‑ERK) in distinct immune cell subsets (T cells, monocytes, NK cells, B cells), providing a direct functional readout of cytokine signalling at the single‑cell level—a parameter that often correlates better with clinical disease activity than bulk cytokine concentrations.

Our Analytical Capabilities: Sensitivity, Multiplexing, and Biological Integration

Our primary immunoassay platform is a fully automated, magnetic bead‑based multiplex chemiluminescent system capable of simultaneously quantifying up to 30 cytokines and related analytes in a single 25‑µL sample, with dynamic ranges spanning 3–4 orders of magnitude. The assays utilise highly specific monoclonal antibody pairs with demonstrated cross‑reactivity < 0.1% to non‑target cytokines and to common interfering substances such as rheumatoid factor, heterophilic antibodies, and biotin. Intra‑assay and inter‑assay coefficients of variation (CV) are consistently below 6% and 9%, respectively, across the entire panel. For samples with suspected matrix effects, we perform a dilutional linearity check and, if needed, confirm results using an independent single‑plex electrochemiluminescence assay or targeted LC‑MS/MS for selected analytes (e.g., TNF‑α, IL‑6, IFN‑γ).

Our functional bioassays are performed in a GLP‑compliant cell culture facility, with routine cell line authentication, mycoplasma testing, and response validation using reference standards. Each assay includes a full calibration curve, positive and negative controls, and a matrix spike‑recovery test. LOQs for bioactivity typically range from 0.1 to 1.0 IU/mL, and we report results with a biological activity index (bioactivity/concentration ratio) that helps identify the presence of functional inhibitors or inactive cytokine isoforms. For the neutralisation assay, we pre‑incubate the patient sample with saturating amounts of the relevant therapeutic antibody (e.g., adalimumab for TNF, tocilizumab for IL‑6) and measure residual bioactivity; the percentage inhibition provides a direct estimate of the drug's functional coverage, with <50% inhibition indicating potential loss of response. Our phospho‑signalling profiling is conducted on a high‑sensitivity flow cytometer with a dedicated panel of phospho‑specific antibodies, and we use a standardised stimulation protocol (with and without cytokine spiking) to assess both basal and inducible signalling capacity. Results are expressed as median fluorescence intensity (MFI) ratios and as a composite signalling activation score (SAS) derived from the weighted sum of phosphoprotein responses across cell types.

Regulatory Compliance and Quality Assurance

All cytokine testing services are conducted under CLIA '88 and CAP accreditation, with immunoassays validated according to CLSI EP‑A2, EP‑A5, and EP‑A7 guidelines. Our bioassays follow the principles of ICH Q2(R1) for biological assay validation, including assessment of precision, accuracy, linearity, and robustness. We participate in external proficiency testing programmes for cytokine immunoassays (UK NEQAS, CAP) and in standardisation efforts for bioactivity measurements where available. Each patient report provides not only numerical values for all measured cytokines, bioactivity units, neutralisation percentages, and signalling indices but also a comprehensive interpretive summary that includes a cytokine network balance score (ratio of pro‑inflammatory to regulatory cytokines), a functional activity matrix (comparing immunoassay vs. bioassay results), and a signalling pathway activation map that visually depicts the dominant activated pathways. Additionally, we provide a clinical decision support section that correlates the cytokine profile with common disease patterns (e.g., Th17‑dominant in psoriatic arthritis, type I interferon‑high in lupus, mixed Th1/Th17 in rheumatoid arthritis) and recommends targeted therapeutic considerations.

Our Distinctive Advantages in Cytokine Testing

Our laboratory distinguishes itself through several unique attributes. First, we offer a truly integrated “three‑layer” assessment—concentration (multiplex immunoassay), function (cell‑based bioactivity), and signalling (intracellular phospho‑flow)—all from a single blood draw, providing a holistic view of the cytokine network that is unmatched in the commercial sector. Second, our multiplex panel is highly customisable; we can add or remove analytes based on specific clinical or research questions, enabling both routine diagnostic and exploratory discovery applications. Third, our functional neutralisation assays are directly applicable to patients receiving biologic therapies, allowing for evidence‑based dose optimisation and early detection of secondary non‑response due to inadequate drug coverage or excess cytokine production.

Fourth, our phospho‑signalling profiling is performed on fresh or cryopreserved PBMCs with strict standardisation, and we have built a large reference database of healthy controls and disease‑specific cohorts, enabling us to report a patient's signalling signature in percentile terms and to detect aberrant pathway activation that may not be reflected in peripheral cytokine levels. Fifth, we provide longitudinal monitoring packages with automated trend analysis, graphical overlays of serial visits, and alert thresholds for significant changes in the cytokine balance or signalling scores, which have been validated to predict disease flares and therapeutic failure in chronic inflammatory disorders. Our expert immunology and rheumatology team is available for in‑depth case consultations, assisting clinicians in integrating complex cytokine data with clinical history and other laboratory findings to guide personalised treatment strategies.

Specimen Types and Clinical Applications

Our cytokine testing is validated on serum, plasma (EDTA, heparin, citrate), cerebrospinal fluid, synovial fluid, bronchoalveolar lavage, and cell culture supernatants. For phospho‑signalling, we require peripheral blood collected in heparinised tubes and processed within 6 hours, or we provide a specialised PBMC isolation kit with stabilising media for overnight shipment. Clinical applications span the diagnosis and monitoring of autoimmune and inflammatory diseases (rheumatoid arthritis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, multiple sclerosis), the evaluation of cytokine release syndromes (e.g., CRS and neurotoxicity in CAR‑T therapy), the assessment of primary and secondary immunodeficiencies (including defects in cytokine production or signalling), the prediction and monitoring of graft‑versus‑host disease, and the therapeutic monitoring of cytokine‑targeting biologics (anti‑TNF, anti‑IL‑6, anti‑IL‑17, anti‑IL‑23, anti‑IL‑1, JAK inhibitors). In oncology, our integrated cytokine and signalling profiles are used to predict immune‑related adverse events and to evaluate the immunomodulatory effects of checkpoint inhibitors and other immunotherapies.

Innovation and Research Partnerships

We are actively developing high‑parameter mass cytometry (CyTOF) panels for simultaneous measurement of over 40 cytokines and intracellular phospho‑proteins at the single‑cell level, and we are validating a digital ELISA platform for ultra‑sensitive detection of low‑abundance cytokines in minimally invasive biofluids such as saliva and dried blood spots. Our research collaborations with academic medical centres contribute to the establishment of dynamic reference ranges, the identification of novel cytokine signatures associated with treatment response and disease progression, and the development of machine‑learning algorithms that integrate multi‑omics data for improved patient stratification. We regularly publish our findings in peer‑reviewed journals and participate in international standardisation initiatives, ensuring that our testing services remain at the forefront of evidence‑based immunology.

Client Support and Service Model

We provide end‑to‑end support, including custom collection kits, pre‑paid shipping, and flexible scheduling for serial testing. Our standard turnaround time is 24‑48 hours for the multiplex immunoassay, 48‑72 hours for functional bioassays, and 72‑96 hours for the complete integrated report with phospho‑signalling. Urgent STAT options are available for acute scenarios such as suspected cytokine storm. All results are delivered via a secure electronic portal with interactive visualisations, trend charts, and exportable data files. We offer volume‑based discounts, free courier collection, and dedicated project management for multi‑centre trials and large epidemiological studies. We also provide complimentary educational webinars, case‑based tutorials, and decision‑support tools to help clinicians navigate the complexity of cytokine data and incorporate it into routine practice.

Conclusion: Cytokine Testing as a Comprehensive Immune Network Biomarker

Cytokine testing, when elevated to a high‑parameter, functionally integrated, and signalling‑resolved discipline, transcends the limitations of simple protein quantification to become a dynamic and holistic assessment of the immune system's operational state. Our laboratory delivers this comprehensive solution—combining ultrasensitive multiplex immunoassay, cell‑based functional bioactivity assays, intracellular phospho‑signalling profiling, and expert clinical interpretation—to empower clinicians with actionable insights for precision immunotherapy, early diagnosis of immune dysregulation, and personalised management of inflammatory, infectious, and neoplastic diseases. Whether the clinical question involves characterising the inflammatory endotype of a rheumatology patient, monitoring biologic therapy efficacy, or diagnosing a primary immunodeficiency with aberrant cytokine signalling, our services provide the accuracy, depth, and clinical relevance essential for optimal decision‑making.

We invite you to partner with us for your cytokine testing needs. Our dedicated immunology team is ready to assist with test selection, custom panel design, protocol optimisation, and result interpretation, ensuring you receive not only reliable laboratory data but also a strategic framework for integrating cytokine and signalling biomarkers into your patient care pathways. Choose our laboratory for excellence in cytokine analytics, supported by scientific rigour, technological innovation, and an unwavering commitment to quality.